
ESC Congress 2023 Begins Soon!



The biggest cardiovascular scientific event of the year - ESC Congress 2023, begins soon! Onsite in Amsterdam and online: 25 to 28 August 2023

There will be nine Hot Line Press Conferences, offering an initial glimpse into the findings of 30 significant studies in cardiovascular disease, along with the opportunity to engage with the researchers behind these studies. These sessions will be the highlight of the Late Breaking Science track, which will encompass clinical trial updates and registry sessions.

The trials presented in Hot Line 1 will include STEP HFpEF, a study comparing the impact of once-weekly semaglutide on individuals with heart failure with preserved ejection fraction (HFpEF) and obesity. NOAH-AFNET 6 delves into oral anticoagulation among patients with atrial high-rate episodes. This trial seeks to answer a crucial clinical inquiry: whether anticoagulant therapy should be employed for individuals with brief episodes of atrial fibrillation (AF). The session will conclude with COP-AF, focusing on AF and myocardial injury, common complications of thoracic surgery associated with elevated mortality, stroke risk, and prolonged hospital stays.

HEART-FID will be featured in Hot Line 2. The trial centres on iron deficiency, prevalent in patients with heart failure and reduced ejection fraction (HFrEF), and assesses the effects of intravenous iron on symptoms and exercise tolerance.

Hot Line 4 will feature a series of trials - ILUMIEN IV, OCTIVUS, and OCTOBER - comparing different approaches to percutaneous coronary intervention (PCI): optical coherence tomography (OCT)-guided, intravascular ultrasound (IVUS)-guided, and angiography-guided. This session will also unveil a real-time updated network meta-analysis, contributing to the quest for optimal PCI approaches.

On 25 August, five ESC Clinical Practice Guidelines will be released. These guidelines encompass the inaugural international guideline covering all cardiomyopathy subtypes, recommendations on acute coronary syndromes, cardiovascular disease management in diabetes patients, endocarditis management, and a focused update on the 2021 Heart Failure Guidelines, taking into account rapidly emerging evidence on treating patients with HFpEF or heart failure with mildly reduced ejection fraction.

Secure your spot by [registering](#) today!

Source: [ESC](#)

Image Credit: ESC

Published on : Wed, 16 Aug 2023